Cell & Gene Manufacturing Process Efficiencies: Best Practice Guide

The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.

Pharma IQ spoke with Elena Meurer, Head of Pharmaceutical and Technical Development at apceth GmbH & Co.KG about the progress required behind this market in regards to process excellence Download this piece to learn more about:

The level of process efficiency behind today’s cell and gene therapies
The two major routes towards improvement Elena Meurer sees for the future
The greatest challenges for the market

Please note: That all fields marked with an asterisk (*) are required.

First Name *

Last Name *

Job Title *

Company Name *

Email Address *

Telephone *

Mobile Telephone

Country *

Where did you hear about us?

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.